24-07-2025
Zydus moves Delhi HC against order restraining sale of its cancer drug
Zydus Lifesciences
on Thursday moved the division bench of the
Delhi High Court
against its single judge's earlier order that temporarily restrained the Ahmedabad-based drug maker from manufacturing, selling
biosimilar
of US pharma giant E.R. Squibb's patent
Nivolumab
, a therapeutic antibody used in the treatment of cancer.
The Division Bench while refusing to stay the single judge's interim order sought response from the US pharma company, which had alleged
patent infringement
of its blockbuster anticancer drug Opdyta (nivolumab) branded as Opdivo in other countries. In India, Nivolumab is being imported and marketed as Opdyta.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
PGDM
Technology
Digital Marketing
Data Science
Others
Management
Cybersecurity
Healthcare
Data Science
Product Management
Public Policy
MBA
others
Design Thinking
Finance
Leadership
Project Management
CXO
MCA
Data Analytics
Artificial Intelligence
Operations Management
healthcare
Degree
Skills you'll gain:
Financial Analysis & Decision Making
Quantitative & Analytical Skills
Organizational Management & Leadership
Innovation & Entrepreneurship
Duration:
24 Months
IMI Delhi
Post Graduate Diploma in Management (Online)
Starts on
Sep 1, 2024
Get Details
While Squibb alleged that Zydus was conducting clinical trials for nivolumab and had plans to launch it during is valid patent period, the Indian company denied the allegations, saying its product ZRC-3276 does not infringe upon the existing patents, was following the regulatory provisions and had applied for a marketing approval with the central drug regulatory agency.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Simoes Filho: Unsold Furniture Liquidation 2024 (Prices May Surprise You)
Unsold Furniture | Search Ads
Learn More
Undo
Zydus argued that its product, ZRC-3276, is bio-similar to Squibb Nivolumab, but bio-similarity by itself does not substantiate infringement as it is based upon product-to-product comparison, whereas, infringement required claim to product mapping.
The generic drug maker claimed that process steps were already known from the prior art and even several techniques for the preparation of human anti-PD1 antibodies were well-known on the priority date of the suit patent.
Live Events
The post-grant opposition that was filed by its subsidiary Zydus Healthcare led to the recommendation for revocation of the suit patent by the Opposition Board, and the said recommendation clearly showed that such a method was commonly employed to produce antibodies, the Ahmedabad-based drug manufacturer claimed.
On July 18, Justice Mini Pushkarna had noted that E.R. Squibb shall suffer irreparable loss in case an interim relief was not granted. Therefore, the single judge had restrained Zydus from selling a biosimilar of Nivolumab till the main suit was decided.
